BCRX - Biocryst Pharmaceuticals Inc.
IEX Last Trade
8.69
0.060 0.690%
Share volume: 1,743,632
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$8.63
0.06
0.70%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-05 | 2022-11-04 | 2023-02-27 | 2023-05-08 | 2023-08-07 | 2023-11-08 | 2024-02-27 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 510.538 M | 558.594 M | 550.000 M | 509.737 M | 529.885 M | 522.924 M | 516.960 M | 467.892 M | |
| Current Assets | 494.853 M | 509.001 M | 516.500 M | 490.883 M | 511.056 M | 502.466 M | 495.966 M | 447.100 M | |
| Inventories | 23.378 M | 27.019 M | 27.533 M | 27.466 M | 27.033 M | 29.630 M | 28.683 M | 29.781 M | |
| Other Current Assets | 11.053 M | 11.070 M | 12.586 M | 15.157 M | 14.112 M | 20.016 M | 19.542 M | 18.381 M | |
| Short Term Investments | 11.053 M | 11.070 M | 12.586 M | 15.157 M | 14.112 M | 20.016 M | 19.542 M | 18.381 M | |
| Total Receivables | 41.491 M | 42.610 M | 50.599 M | 48.639 M | 57.667 M | 53.646 M | 56.950 M | 60.586 M | |
| Current Cash | 417.483 M | 426.858 M | 424.310 M | 398.158 M | 410.670 M | 397.590 M | 388.987 M | 336.554 M | |
| Total Non-current Assets | 15.685 M | 49.593 M | 33.500 M | 18.854 M | 18.829 M | 20.458 M | 20.994 M | 20.792 M | |
| Property Plant Equipment | 8.702 M | 8.464 M | 8.617 M | 8.376 M | 8.438 M | 8.999 M | 7.910 M | 7.831 M | |
| Other Assets | 6.983 M | 6.797 M | 6.806 M | 7.046 M | 6.946 M | 11.459 M | 13.084 M | 12.961 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 510.538 M | 558.594 M | 550.000 M | 509.737 M | 529.885 M | 522.924 M | 516.960 M | 467.892 M | |
| Total liabilities | 723.770 M | 801.253 M | 844.597 M | 838.024 M | 918.598 M | 933.910 M | 972.488 M | 944.059 M | |
| Total current liabilities | 95.390 M | 81.637 M | 105.514 M | 85.157 M | 93.498 M | 90.763 M | 149.988 M | 119.921 M | |
| Accounts Payable | 12.024 M | 8.622 M | 14.356 M | 6.254 M | 13.889 M | 10.567 M | 20.893 M | 11.910 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 25.155 M | 27.664 M | |
| Long term debt | 622.182 M | 713.648 M | 733.279 M | 746.933 M | 819.297 M | 833.181 M | 814.110 M | 815.542 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -213.232 M | -242.659 M | -294.597 M | -328.287 M | -388.713 M | -410.986 M | -455.528 M | -476.167 M | |
| Common stock | 185.605 M | 186.180 M | 186.949 M | 188.509 M | 189.118 M | 189.644 M | 201.521 M | 206.064 M | |
| Retained earnings | -1.341 B | -1.383 B | -1.455 B | -1.508 B | -1.583 B | -1.619 B | -1.681 B | -1.717 B |